Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : IONS save search
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
Published: 2024-04-07 (Crawled : 16:20) - prnewswire.com
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
| Email alert
Add to watchlist
positive for results study
Ionis to present at upcoming investor conferences
Published: 2024-04-01 (Crawled : 11:00) - prnewswire.com
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: -3.0%
H: 1.62%
C: 1.45%
Ionis to hold olezarsen Phase 3 data webcast
Published: 2024-03-28 (Crawled : 11:00) - prnewswire.com
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting
Published: 2024-03-25 (Crawled : 13:30) - biospace.com/
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: -0.14%
H: 3.12%
C: 2.93%
positive meeting cardiology
Health Canada Accepts for Review New Drug Submission for Tofersen for Treatment of Rare, Genetic Form of ALS
Published: 2024-03-19 (Crawled : 12:30) - biospace.com/
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: -0.33%
H: 1.89%
C: 0.64%
drug health genetic als review treatment canada submission
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH
Published: 2024-03-13 (Crawled : 11:00) - prnewswire.com
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: 0.69%
H: 1.1%
C: -0.71%
ion224 positive treatment results study
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
Published: 2024-03-06 (Crawled : 12:30) - globenewswire.com
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: 0.05%
H: 1.32%
C: 0.18%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.11%
H: 1.16%
C: 0.04%
spinraza biomarker potential therapy
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
Published: 2024-03-05 (Crawled : 12:00) - globenewswire.com
PRAX | $46.88 0.62% 0.62% 350K
|
Health Technology
|
| O: 2.36%
H: 0.88%
C: -4.14%
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: -0.2%
H: 0.83%
C: -1.32%
precision update financial results
Ionis announces new chief global product strategy officer to lead next phase of commercial growth
Published: 2024-02-29 (Crawled : 14:00) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -3.11%
H: 0.0%
C: -0.24%
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: 0.82%
H: 0.33%
C: -3.64%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.28%
H: 0.06%
C: -1.55%
global commercial growth
Ionis to present at upcoming investor conferences - February 28, 2024
Published: 2024-02-28 (Crawled : 13:00) - biospace.com/
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: -0.59%
H: 1.12%
C: -1.25%
Ionis to present at upcoming investor conferences
Published: 2024-02-28 (Crawled : 12:00) - prnewswire.com
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: -0.59%
H: 1.12%
C: -1.25%
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
Published: 2024-02-23 (Crawled : 12:00) - globenewswire.com
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: 0.25%
H: 2.95%
C: 2.88%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.43%
H: 1.06%
C: -0.05%
qalsody first chmp genetic positive treat therapy
Ionis reports fourth quarter and full year 2023 financial results
Published: 2024-02-21 (Crawled : 12:00) - prnewswire.com
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: 3.54%
H: 0.68%
C: -5.2%
year financial results
Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome
Published: 2024-02-15 (Crawled : 13:00) - biospace.com/
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: -1.53%
H: 3.16%
C: -6.29%
fda drug designation
Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy
Published: 2024-02-08 (Crawled : 12:00) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -8.5%
H: 2.46%
C: 2.46%
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: 0.2%
H: 1.37%
C: 0.68%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -6.81%
H: 3.02%
C: 2.42%
fda granted designation eplontersen
Ionis to hold fourth quarter and full year 2023 financial results webcast
Published: 2024-02-07 (Crawled : 12:00) - prnewswire.com
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: 0.02%
H: 0.98%
C: 0.83%
year financial results
Vect-Horus Enters Exclusive License Agreement with Ionis Pharmaceuticals to Advance Systemic Delivery of RNA-Targeted Medicines for Neurological Diseases
Published: 2024-01-30 (Crawled : 15:00) - biospace.com/
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: -0.56%
H: 0.5%
C: 0.35%
license pharmaceuticals neurological agreement
Relapsing/Refractory Multiple Myeloma Market to Observe Stupendous Growth by 2032, Estimates DelveInsight | Leading Companies - Bristol-Myers Squibb, Allogene Therapeutics, Genentech, Pfizer, Ionis Pharmaceuticals, AbbVie, Amgen
Published: 2024-01-25 (Crawled : 22:00) - prnewswire.com
ACLX | $51.67 -5.19% -5.48% 740K
|
|
| O: 0.2%
H: 5.99%
C: 5.65%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
MTEM | $1.455 -2.02% -2.06% 13K
|
Health Technology
|
| O: -2.94%
H: 3.03%
C: 3.03%
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: 0.43%
H: 0.27%
C: -0.6%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.66%
H: 0.64%
C: -1.11%
IMAB | $1.81 0.56% 0.55% 340K
|
Health Technology
|
| O: 1.1%
H: 0.27%
C: -1.64%
companies growth market
Transthyretin Amyloidosis Market is Predicted to Exhibit Remarkable Growth by 2032, Predicts DelveInsight | Key Players - Attralus, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, AstraZeneca, Alexion Pharmaceuticals, Novo Nordisk
Published: 2024-01-24 (Crawled : 23:00) - prnewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: 0.49%
H: 0.0%
C: -0.05%
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: 0.38%
H: 2.34%
C: 1.56%
key growth market
Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema
Published: 2024-01-22 (Crawled : 15:30) - biospace.com/
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: 0.55%
H: 1.11%
C: -0.49%
positive topline results study
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.